Oppenheimer Maintains Outperform on AQST Aquestive Therapeutics Feb 2026

Oppenheimer maintained an Outperform rating on AQST (Aquestive Therapeutics, Inc.) on February 2, 2026. This AQST analyst rating frames Oppenheimer’s view that the FDA Complete Response Letter is a potential clearing event for the company. The firm kept the rating despite short-term selling, with the stock down 3.42% ($0.15) after the call. Market cap stands at $406,859,288, and no new price target was published with the note. We use Meyka AI-powered market analysis to explain what this rating means for investors.

AQST analyst rating: Oppenheimer Maintains Outperform

Oppenheimer formally maintained Outperform on February 02, 2026 at 10:35 AM. The firm described the FDA Complete Response Letter as a “clearing event” in coverage noted by TheFly. Read Oppenheimer’s commentary at TheFly.

What Oppenheimer’s Outperform rating means for investors

An Outperform rating signals Oppenheimer expects AQST to beat average sector returns. The firm expects the FDA feedback to reduce regulatory risk and unlock value over time. Investors should view this as a positive analyst view, not a guarantee of near-term gains.

Price reaction, market cap, and immediate implications

Shares fell 3.42% ($0.15) on the news despite the maintained rating. That drop shows investors priced in near-term uncertainty around the CRL. The company market cap is $406,859,288, a reminder that liquidity and float size can amplify headline moves.

Context on historical analyst coverage for AQST analyst rating

Analyst coverage for Aquestive Therapeutics has been limited relative to larger biotech peers. Oppenheimer’s note is notable because the firm provides regular sector research and risk framing. There were no new price targets published with this note, keeping prior targets unchanged.

How the maintained rating links to AQST price target and forecasts

Oppenheimer offered no fresh price target in the Feb 2 note, so consensus targets remain the market reference. Without a new target, the maintained Outperform communicates continued conviction in fundamentals and regulatory progress. Investors should monitor any future target revisions as more FDA feedback arrives.

Meyka AI grade and platform view on the AQST analyst rating

Meyka AI rates AQST with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. See our platform page for real-time tracking at AQST on Meyka.

Final Thoughts

Oppenheimer’s decision to maintain Outperform on AQST on February 2, 2026 keeps analyst sentiment constructive despite short-term selling. The note treats the FDA Complete Response Letter as a potential clearing event rather than a fundamental setback. Investors should weigh Oppenheimer’s view against market reaction, which pushed the stock down 3.42% ($0.15) as traders re-priced near-term outcomes.

For investors, the maintained rating means monitor regulatory updates and watch for formal price target revisions. Meyka AI rates AQST with a grade of B+ based on benchmark, sector, growth, and analyst inputs. These grades are not guaranteed and we are not financial advisors. Use the maintained Outperform as one input in a broader investment checklist, including balance sheet strength and upcoming FDA interactions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.